Pfizer Pharmaceuticals Korea carry out patent support program of ‘Ibrance,’ breast cancer treatment
Pfizer Pharmaceuticals Korea will start a patient support program for ‘Ibrance(generic name: palbociclib),’ a breast cancer therapy.
According to the company, it internally had discussions about the program for the past several months and decided to carry out it within the coming June. The progr...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.